Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

Core Viewpoint - Palvella Therapeutics, Inc. is set to report its third quarter 2025 financial results on November 11, 2025, and will host a conference call for investors to discuss the results and provide a corporate update [1]. Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases that lack FDA-approved treatments [3]. - The company is developing a pipeline of product candidates utilizing its patented QTORIN™ platform, with a focus on serious, rare genetic skin diseases [3]. - The lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in various clinical trials, including Phase 3 and Phase 2 studies for different conditions [3]. Upcoming Events - A conference call for investors will take place at 8:30 a.m. ET on November 11, 2025, following the financial results announcement [1]. - The call will be accessible via a live webcast and by phone, with a replay available for 90 days post-event [2].